HarNeedi - Healthcare & Pharma Job Portal

Magnetic opportunities for Indian Pharma : Indian medicine companies are presented with attractive growth opportunities because of consolidation of global generics, according to Moody’s Investors Service (American ratings, research, and risk analysis firm). Drug producers here exhibit stronger business profiles compared to global peers due to their geographic diversity and strong product pipeline for developed markets, states the firm’s latest report, “Indian Pharmaceutical Companies – A Deep Dive”. The report also states that the Indian drug makers may explore and benefit from some overseas Merger &acquisition (M&A) on the back of consolidation of global generics. Large promoter ownerships may dissuade M&A activity domestically, it adds. “The global pharmaceutical industry is undergoing consolidation, driven by a desire for product and pipeline diversity, scale and pricing power,” states the report. “Historical acquisitions have been small in the Indian p...

Biopharma companies are crabbing up their drug research & development spending after staying stable all the way through last couple of years. According to industry sources,  research & development investments  will top $136 billion in 2013, up from $ 134 billion (2012); also the R&D expenditures estimated to exceed ($ 149 billion) by 2017. Drug Development Costs:  Average cost to develop a drug Early 2000s = $1.2 billion approx Late 1990s = $800 million Mid 1980s = $320 million 1970s = $140 million New medicine development – Big investors: According to recent industry surveys: NovoNordisk will have the fastest growth in Research & Development spending, from $1.8 billion in 2011 to $3.1 billion in 2018, an 8 % increase in investments. Novartis is predicted to spend on R&D the most $10.1 billion – by 2018. Roche is expected to spend $8.7 billion. Merck & Co., is expected to spend $7.6 billion. GlaxoSmithKline, is expected to spend $7...

India is the biggest manufacturer and exporter of generic drugs on globe and considered as the pharmacy of the globe. However many Indian pharma companies find it difficult to survive in global markets due to the heavy competition, lack of market research knowledge, complex regulatory results and not embracing the latest digital technologies adopted by global companies. Innovation brings both opportunity and change, and this is true with emerging point of care technology. There is a pressing need for help in the three critical areas of Prevention, Diagnosis and Monitoring.But extremely restrictive regulations, the presence of multiple key stakeholders, a slow-to-adopt culture and other challenges distinguish healthcare from the retail and finance sectors, which have flourished with their implementations of digital technologies. Changes in regulatory, patent and market trends will drive opportunities for generic drugs and hence very big opportunities for Indian pharmaceutical compan...